This volume is the proceedings of the William Harvey Research Conference held in Cannes, France, on the 20th and 21st March, 1997. It describes the present knowledge of the structures of the cyclooxygenase isoforms and the experimental and clinical effects of selective inhibitors of cyclooxygenase-2. The pathophysiological significance of the cyclooxygenase enzymes in tumorigenesis, programmed cell death, vascular disease and asthma is also covered.
Preface. 1. Mechanism of Action of Anti-Inflammatory Drugs: An Overview; J.R. Vane, R.M. Botting. 2. The Structure of Human COX-2 and Selective Inhibitors; M.F. Browner. 3. Differential Inhibition of COX-1 and COX-2 by NSAIDs: A Summary of Results Obtained Using Various Test Systems; M. Pairet, et al. 4. COX-2 in Brain and Retina: Role in Neuronal Survival; N.G. Bazan, et al. 5. COX-2 and Apoptosis: NSAIDs as Effectors of Programmed Cell Death; D.L. Simmons, et al. 6. Inhibition of Intestinal Tumorigenesis via Selective Inhibition of COX-2; R.N. DuBois, et al. 7. Cyclooxygenase Enzymes in Human Vascular Disease; C. Patrono, et al. 8. Gastrointestinal Effects of NSAIDs; C.J. Hawkey. 9. Renal Side-Effects of NSAIDs: Role of COX-1 and COX-2; J.C. Frolich, D.O. Stichtenoth. 10. Aspirin-Induced Asthma and Cyclooxygenases; R.J. Gryglewski. 11. New Classification of Aspirin-like Drugs; H. Fenner. 12. New Highly Selective COX-2 Inhibitors; A.W. Ford-Hutchinson. 13. Specific COX-2 Inhibitors: From Bench to Bedside; P. Isakson, et al. 14. Meloxicam: Selective COX-2 Inhibition in Clinical Practice; D.E. Furst.